ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

13 träffar

Bibliografisk träff 2017-08-10

Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp.

Gourdy P, Cazals L, Thalamas C, Sommet A, Calvas F, Galitzky M, Vinel C, Dray C, Hanaire H, Castan-Laurell I, Valet P.

Diabetes Obes Metab · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1111/dom.13055

Bibliografisk träff 2017-02-28

[Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13.

Yang P, Kuc RE, Brame AL, Dyson A, Singer M, Glen RC, Cheriyan J, Wilkinson IB, Davenport AP, Maguire JJ.

Front Neurosci · research-article; journal article · DOI 10.3389/fnins.2017.00092

Bibliografisk träff 2017-02-09

Post-infarct treatment with [Pyr1]apelin-13 exerts anti-remodelling and anti-apoptotic effects in rats' hearts.

Azizi Y, Imani A, Fanaei H, Khamse S, Parvizi MR, Faghihi M.

Kardiol Pol · journal article · DOI 10.5603/kp.a2017.0022

Bibliografisk träff 2017-01-30

Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension.

Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ, Davenport AP.

Circulation · research-article; journal article · DOI 10.1161/circulationaha.116.023218

Bibliografisk träff 2016-12-24

Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice.

Ishimaru Y, Sumino A, Kajioka D, Shibagaki F, Yamamuro A, Yoshioka Y, Maeda S.

J Pharmacol Sci · journal article · DOI 10.1016/j.jphs.2016.12.002

Bibliografisk träff 2016-12-01

[Effects of (Pyr1)apelin-13 on the proliferation and activation of Jarkat T lymphocyte].

Wei M, Gan L, Hou J, Chen L, Liu Y, Ren L.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi · journal article

Bibliografisk träff 2016-08-01

Agonist-induced internalization and desensitization of the apelin receptor.

Pope GR, Tilve S, McArdle CA, Lolait SJ, O'Carroll AM.

Mol Cell Endocrinol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.mce.2016.07.040

Bibliografisk träff 2015-09-22

Downregulation of apelin in the human placental chorionic villi from preeclamptic pregnancies.

Yamaleyeva LM, Chappell MC, Brosnihan KB, Anton L, Caudell DL, Shi S, McGee C, Pirro N, Gallagher PE, Taylor RN, Merrill DC, Mertz HL.

Am J Physiol Endocrinol Metab · research support, non-u.s. gov't; research-article; journal article · DOI 10.1152/ajpendo.00272.2015

Bibliografisk träff 2014-10-13

[Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction.

Serpooshan V, Sivanesan S, Huang X, Mahmoudi M, Malkovskiy AV, Zhao M, Inayathullah M, Wagh D, Zhang XJ, Metzler S, Bernstein D, Wu JC, Ruiz-Lozano P, Rajadas J.

Biomaterials · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.biomaterials.2014.08.045

Bibliografisk träff 2014-07-01

Stability and degradation patterns of chemically modified analogs of apelin-13 in plasma and cerebrospinal fluid.

Murza A, Belleville K, Longpré JM, Sarret P, Marsault É.

Biopolymers · research support, non-u.s. gov't; journal article · DOI 10.1002/bip.22498

Bibliografisk träff 2013-05-29

Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction.

Azizi Y, Faghihi M, Imani A, Roghani M, Nazari A.

Peptides · research support, non-u.s. gov't; journal article · DOI 10.1016/j.peptides.2013.05.006

Bibliografisk träff 2009-07-13

[Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease.

Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP.

Hypertension · research support, non-u.s. gov't; journal article · DOI 10.1161/hypertensionaha.109.134619

Bibliografisk träff 2005-02-01

Central and peripheral cardiovascular actions of apelin in conscious rats.

Kagiyama S, Fukuhara M, Matsumura K, Lin Y, Fujii K, Iida M.

Regul Pept · journal article · DOI 10.1016/j.regpep.2004.07.033

Gå till forskningen.

Publikationer i urvalet

Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp.

[Pyr<sup>1</sup>]Apelin-13<sub>(1-12)</sub> Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr<sup>1</sup>]Apelin-13.

Post-infarct treatment with [Pyr1]apelin-13 exerts anti-remodelling and anti-apoptotic effects in rats' hearts.

Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension.

Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice.

[Effects of (Pyr<sup>1</sup>)apelin-13 on the proliferation and activation of Jarkat T lymphocyte].

Agonist-induced internalization and desensitization of the apelin receptor.

Downregulation of apelin in the human placental chorionic villi from preeclamptic pregnancies.

[Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction.

Stability and degradation patterns of chemically modified analogs of apelin-13 in plasma and cerebrospinal fluid.

Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction.

[Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease.

Central and peripheral cardiovascular actions of apelin in conscious rats.